• Vaccine Ontology ID: VO_0004599
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• Glycoprotein B gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3 (Hwang et al., 1999)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004341
• Type: DNA vaccine
• Status: Clinical trial
• Host Species as Laboratory Animal Model: Human
• Glycoprotein B gene engineering:
  • Type: DNA vaccine construction
  • Description: This DNA vaccine expressed the major hCMV surface glycoprotein B (Schleiss, 2009).
  • Detailed Gene Information: Click Here.
• UL83 gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: VCL-CB01 increased T-cell responses compared with placebo (Schleiss, 2009).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: Neutralizing antibody was developed, and the percent reduction of input infectivity in 1:100 diluted sera was 74.5% in three-times immunized groups. The induction of neutralizing antibody with HCMV gB in this study might be useful to attenuate or prevent HCMV infection (Hwang et al., 1999).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: Preclinical investigation of the hCMV gB/pp65 DNA vaccine was initially conducted in mice. When formulated in PBS, lone gB and pp65 plasmids were highly immunogenic, but vaccination with the bivalent vaccine reduced immune responses to each antigen by 2.8- and 4-fold of the lone values, respectively. However, formulating the bivalent vaccine with 02A significantly (p = 0.048) increased the antigen-specific immune responses relative to those induced with the bivalent vaccine in PBS, as well as completely abrogating a decrease in pp65-specific T-cell responses (Schleiss, 2009).